|
1
|
Bareschino MA, Schettino C, Rossi A,
Maione P, Sacco PC, Zeppa R and Gridelli C: Treatment of advanced
non small cell lung cancer. J Thorac Dis. 3:122–133. 2011.
|
|
2
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
asian patients with advanced non-small-cell lung cancer of
adeno-carcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou
C, Liao M, Mok T, Jiang H, Duffield E and Fukuoka M: Phase III,
randomized, open-label, first-line study in asia of gefitinib
versus carbo-platin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer: Evaluation of patients
recruited from mainland China. Asia-Pac J Clin Oncol. 8:232–243.
2012. View Article : Google Scholar
|
|
4
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thongprasert S, Duffield E, Saijo N, Wu
YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, et al:
Health-related quality-of-life in a randomized phase III first-line
study of gefi-tinib versus carboplatin/paclitaxel in clinically
selected patients from Asia with advanced NSCLC (IPASS). J Thorac
Oncol. 6:1872–1880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ellis PM, Coakley N, Feld R, Kuruvilla S
and Ung YC: Use of the epidermal growth factor receptor inhibitors
gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the
treatment of non-small-cell lung cancer: A systematic review. Curr
Oncol. 22:e183–e215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jackman D, Pao W, Riely GJ, Engelman JA,
Kris MG, Janne PA, Lynch T, Johnson BE and Miller VA: Clinical
definition of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar
|
|
8
|
Gao Z, Chen W, Zhang X, Cai P, Fang X, Xu
Q, Sun Y and Gu Y: Icotinib, a potent and specific EGFR tyrosine
kinase inhibitor, inhibits growth of squamous cell carcinoma cell
line A431 through negatively regulating AKT signaling. Biomed
Pharmacother. 67:351–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen X, Zhu Q, Liu Y, Liu P, Yin Y, Guo R,
Lu K, Gu Y, Liu L, Wang J, et al: Icotinib is an active treatment
of non-small-cell lung cancer: A retrospective study. PLoS One.
9:e958972014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu
Z, Xue C, Zhang J, Zhang J, Ma Y, et al: Network meta-analysis of
erlotinib, gefitinib, afatinib and icotinib in patients with
advanced non-small-cell lung cancer harboring EGFR mutations. PLoS
One. 9:e852452014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi Y, Zhang L, Liu X, Zhou C, Zhang L,
Zhang S, Wang D, Li Q, Qin S, Hu C, et al: Icotinib versus
gefitinib in previously treated advanced non-small-cell lung cancer
(ICOGEN): A randomised, double-blind phase 3 non-inferiority trial.
Lancet Oncol. 14:953–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Antonicelli A, Cafarotti S, Indini A,
Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF,
Bonifati LG, et al: EGFR-targeted therapy for non-small cell lung
cancer: Focus on EGFR oncogenic mutation. Int J Med Sci.
10:320–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou C and Yao LD: Strategies to improve
outcomes of patients with EGRF-mutant non-small cell lung cancer:
Review of the literature. J Thorac Oncol. 11:174–186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meggio F and Pinna LA:
One-thousand-and-one substrates of protein kinase CK2? FASEB J.
17:349–368. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ortega CE, Seidner Y and Dominguez I:
Mining CK2 in cancer. PLoS One. 9:e1156092014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Torres J and Pulido R: The tumor
suppressor PTEN is phosphorylated by the protein kinase CK2 at its
C terminus. implications for PTEN stability to proteasome-mediated
degradation. J Biol Chem. 276:993–998. 2001. View Article : Google Scholar
|
|
19
|
Cozza G, Mazzorana M, Papinutto E, Bain J,
Elliott M, di Maira G, Gianoncelli A, Pagano MA, Sarno S, Ruzzene
M, et al: Quinalizarin as a potent, selective and cell-permeable
inhibitor of protein kinase CK2. Biochem J. 421:387–395. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Daya-Makin M, Sanghera JS, Mogentale TL,
Lipp M, Parchomchuk J, Hogg JC and Pelech SL: Activation of a
tumor-associated protein kinase (p40TAK) and casein kinase 2 in
human squamous cell carcinomas and adenocarcinomas of the lung.
Cancer Res. 54:2262–2268. 1994.PubMed/NCBI
|
|
21
|
Faust M, Schuster N and Montenarh M:
Specific binding of protein kinase CK2 catalytic subunits to
tubulin. FEBS Lett. 462:51–56. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee CK, Kim S, Lee JS, Lee JE, Kim SM,
Yang IS, Kim HR, Lee JH, Kim S and Cho B: Next-generation
sequencing reveals novel resistance mechanisms and molecular
heterogeneity in EGFR-mutant non-small cell lung cancer with
acquired resistance to EGFR-TKIs. Lung Cancer. 113:106–114. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Maira G, Salvi M, Arrigoni G, Marin O,
Sarno S, Brustolon F, Pinna LA and Ruzzene M: Protein kinase CK2
phosphorylates and upregulates Akt/PKB. Cell Death Differ.
12:668–677. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duncan JS and Litchfield DW: Too much of a
good thing: The role of protein kinase CK2 in tumorigenesis and
prospects for therapeutic inhibition of CK2. Biochim Biophys Acta.
1784:33–47. 2008. View Article : Google Scholar
|
|
26
|
Hay N: Interplay between FOXO, TOR, and
Akt. Biochim Biophys Acta. 1813:1965–1970. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu SG and Shih JY: Management of acquired
resistance to EGFR TKI-targeted therapy in advanced non-small cell
lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chua MM, Ortega CE, Sheikh A, Lee M,
Abdul-Rassoul H, Hartshorn KL and Dominguez I: CK2 in cancer:
Cellular and biochemical mechanisms and potential therapeutic
target. Pharmaceuticals (Basel). 10. pp. E182017, View Article : Google Scholar
|
|
29
|
Yaylim I and Isbir T: Enhanced casein
kinase II (CK II) activity in human lung tumours. Anticancer Res.
22:215–218. 2002.PubMed/NCBI
|
|
30
|
Hung MS, Xu Z, Chen Y, Smith E, Mao JH,
Hsieh D, Lin YC, Yang CT, Jablons DM and You L: Hematein, a casein
kinase II inhibitor, inhibits lung cancer tumor growth in a murine
xenograft model. Int j Oncol. 43:1517–1522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Q, Li K, Yang T, Zhang S, Zhou Y, Li Z,
Xiong J, Zhou F, Zhou X, Liu L, et al: Association of protein
kinase CK2 inhibition with cellular radiosensitivity of non-small
cell lung cancer. Sci Rep. 7:161342017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim J and Kim SH: Druggability of the CK2
inhibitor CX-4945 as an anticancer drug and beyond. Arch Pharm Res.
35:1293–1296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ku MJ, Park JW, Ryu BJ, Son YJ, Kim SH and
Lee SY: CK2 inhibitor CX4945 induces sequential inactivation of
proteins in the signaling pathways related with cell migration and
suppresses metastasis of A549 human lung cancer cells. Bioorg Med
Chem Lett. 23:5609–5613. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Di Maira G, Brustolon F, Bertacchini J,
Tosoni K, Marmiroli S, Pinna LA and Ruzzene M: Pharmacological
inhibition of protein kinase CK2 reverts the multidrug resistance
phenotype of a CEM cell line characterized by high CK2 level.
Oncogene. 26:6915–6926. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Asati V, Mahapatra DK and Bharti SK:
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as
anticancer agents: Structural and pharmacological perspectives. Eur
J Med Chem. 109:314–341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lieber M, Smith B, Szakal A, Nelson-Rees W
and Todaro G: A continuous tumor-cell line from a human lung
carcinoma with properties of type II alveolar epithelial cells. Int
J Cancer. 17:62–70. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Greve G, Schiffmann I, Pfeifer D, Pantic
M, Schuler J and Lubbert M: The pan-HDAC inhibitor panobinostat
acts as a sensitizer for erlotinib activity in EGFR-mutated and
-wildtype non-small cell lung cancer cells. BMC Cancer. 15:9472015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sos ML, Koker M, Weir BA, Heynck S,
Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P,
et al: PTEN loss contributes to erlotinib resistance in EGFR-mutant
lung cancer by activation of Akt and EGFR. Cancer Res.
69:3256–3261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ritt DA, Zhou M, Conrads TP, Veenstra TD,
Copeland TD and Morrison DK: CK2 is a component of the KSR1
scaffold complex that contributes to raf kinase activation. Curr
Biol. 17:179–184. 2007. View Article : Google Scholar
|
|
40
|
Parker R, Clifton-Bligh R and Molloy MP:
Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a
role for the lethal synergism of dual BRAF and CK2 inhibition. Mol
Cancer Ther. 13:1894–1906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
So KS, Rho JK, Choi YJ, Kim SY, Choi CM,
Chun YJ and Lee JC: AKT/mTOR down-regulation by CX-4945, a CK2
inhibitor, promotes apoptosis in chemorefractory non-small cell
lung cancer cells. Anticancer Res. 35:1537–1542. 2015.PubMed/NCBI
|
|
42
|
Yip PY: Phosphatidylinositol
3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR)
signaling pathway in non-small cell lung cancer. Transl Lung Cancer
Res. 4:165–176. 2015.PubMed/NCBI
|
|
43
|
Reungwetwattana T and Dy GK: Targeted
therapies in development for non-small cell lung cancer. J
Carcinog. 12:222013. View Article : Google Scholar
|
|
44
|
Zer A and Leighl N: Promising targets and
current clinical trials in metastatic non-squamous NSCLC. Front
Oncol. 4:3292014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bliesath J, Huser N, Omori M, Bunag D,
Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O'Brien SE, Lim JK,
et al: Combined inhibition of EGFR and CK2 augments the attenuation
of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer
Lett. 322:113–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
So KS, Kim CH, Rho JK, Kim SY, Choi YJ,
Song JS, Kim WS, Choi CM, Chun YJ and Lee JC:
Autophagosome-mediated EGFR down-regulation induced by the CK2
inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung
cancer cells with resistance by T790M. PLoS One. 9:e1140002014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ke EE and Wu YL: EGFR as a pharmacological
target in EGFR-mutant non-small-cell lung cancer: Where do we stand
now? Trends Pharmacol Sci. 37:887–903. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Morgillo F, Della Corte CM, Fasano M and
Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung
cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
|
